From 2-year delay to simultaneous publication the journey from MENTOR to MAJESTY
The Filtrate
Joel Topf @kidney_boy
Swapnil Hiremath @hswapnil.medsky.social
Natalie Freidin Program director at Medical University of South Carolina
AC @medpeedskidneys.bsky.social
Special Guests
Fernando Fervenza Professor of Medicine, The Mayo Clinic
Editing
Vip Vergues
The Kidney Connection written and performed by Timothy Yau
Show Notes
MENTOR NephJC | NEJM | Freely Filtered episode 7
PLA2r in 2009 M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy NEJM
MAJESTY NephJC | NEJM Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
Giuseppe Remuzzi discovers rituximab works in primary membranous. Rituximab for idiopathic membranous nephropathy The Lancet 2002
Fervenza’s 15-person study of Rituximab treatment of idiopathic membranous nephropathy Kidney International 2008.
Larry Beck’s NEJM PLA2r study M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy NEJM 2009
2011 (not 2010) JASN paper where using banked serum from two prior rituximab studies in membranous nephropathy, Beck and Fervenza showed that declines in anti-PLA2R antibodies preceded reductions in proteinuria and predicted subsequent clinical remission, establishing the concept that immunologic remission precedes clinical remission. Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy PubMed
The National Institute of Animal Health…a Fervenza fiction
Robert A. Star, M.D. NIH
Daniel C. Cattran, M.D. NephCure
Tubular Secretions
Swap do not go to see Mandalorian and Grogu or Supergirl
AC doing nothing
Natalie The Wealth Ladder by Nick Maggiulli (amazon)
Fernando South Portugal and GlomCon Hawaii
Joel The Boundary Waters Canoe Area